Myelodysplasia (MDS) is a bone marrow syndrome characterized by the presence of unhealthy (dysplastic) stem cells that displace the healthy ones, disrupting their ability to mature and develop properly. These healthy stem cells are responsible for generating essential components like red blood cells (which transport oxygen), white blood cells (crucial for fighting infections), and platelets (important for clotting). However, the unhealthy cells can suppress the function of the healthy ones, leading to various dysfunctions.
When the red blood cells are affected, patients experience symptoms such as breathlessness, fatigue, and weakness. Furthermore, this condition can give rise to other issues, including heart failure. As a solution, patients often require transfusions of red blood cells, although this approach also presents potential risks. With each blood transfusion, the patient receives a significant amount of iron, which can have adverse effects on the heart and liver. Striking the right balance is challenging.
Normally, our kidneys support the production of red blood cells from bone marrow by releasing an enzyme called erythropoietin. In individuals with MDS, extra erythropoietin is sometimes administered to stimulate the production of more red blood cells. However, this approach doesn’t always yield the desired results, especially if the primary problem lies in the damaged stem cells within the bone marrow.
In the past, there existed a therapy reserved for patients who didn’t respond to erythropoietin – Luspatercept, also known as Reblozyl. Unfortunately, patients were required to undergo erythropoietin treatment first before gaining access to what was believed to be a more effective therapy. This sequence has changed. Recent study results have revealed that MDS patients were more likely to respond positively to Reblozyl compared to erythropoietin. Notably, patients who frequently needed blood transfusions had an almost 60% chance of reducing or eliminating the need for them with Reblozyl. This breakthrough led the FDA to approve the use of Reblozyl without the prerequisite of prior erythropoietin treatment.
Reblozyl represents a groundbreaking class of medication that facilitates the maturation of red blood cells stuck in the development process. While potential side effects include headaches and a risk of blood clots, among others, it’s essential to recognize that there’s no universally applicable treatment for every patient. Nevertheless, this development marks a significant stride in enhancing the care for individuals affected by MDS for both eliminating blood transfusions and improving quality of life. Speak with your physician for further questions on this development
About the author
Engage with Dr. Landau’s expertise and ignite your curiosity on “Ask MedOnCMD” as he invites you to explore the vast landscape of oncology with a fresh outlook.